Slide 1: Corporate Update
Corporate Update May 20, 2013 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements about Elan’s financial condition, results of operations and business prospects that involve substantial risks and uncertainties. A list and description of these risks, uncertainties and other matters can be found in Elan’s A
Slide 3: Agenda
Agenda 1. Ongoing Objectives 2. Overview 3. Theravance 4. AOP Orphan 5. Speranza Therapeutics 6. Capital Structure 7. Elan Today
Slide 4: Ongoing Objectives
Ongoing Objectives • P&L Growth: Self Funding To Support Long Cycle Business • Establish Optionality Value For Late Stage (Ph II & III ) Pipeline Assets • Diversification (Science/Molecules, Therapeutic Areas, Geographies) • Leverage Business & Financial Structure To Maximize Value & Cash Flow • Ens
Slide 5: Achieved To Date… Strategic Initiatives…
Achieved To Date… Strategic Initiatives… Overview J&J AIP business construct restructuring Sale of EDT to Alkermes Spin-off of Prothena Tysabri value unlocking Significantly Improved Capital Structure Paid off all debt ($2.4 Bn in 2006) Returned $1.0 Bn to shareholders Maintained high cash levels Tr
Slide 6: Elan 2009 vs. 2013 Pro Forma: Simplified, lower risk business
Elan 2009 vs. 2013 Pro Forma (1)(2) Simplified, lower risk business with enhanced focus yielding greater income diversification for investors Elan Transformation Total Debt ($ MM) Total Cash ($ MM) Total Shares (MM) Total Principal Sites Total Employees Notes: 1. PF Adjustments include adjustments f
Slide 7: Three Pillars for Sustainable Growth
- Lower Risk with Growth, Geographical Diversification and Embedded Option Value Three Pillars for Sustainable Growth
Slide 8: Theravance Overview
Theravance Overview
Slide 9: Respiratory Market
GSK 44% Respiratory Market * Bank of America (COPD & Asthma) – Feb, 2013 IMS Health and Chronic Obstructive Disease August 2010 Decision Resource Inc. September 2010 Significant Growth drivers for the macro Respiratory Market • • • $22.5bn* CAGR 2.7% Demographics: increased aging, increased prevalan
Slide 10: Theravance Transaction
Every $1bn of in-market sales could generate up to ~$25m of net income to Elan Theravance Transaction
Slide 11: AOP Orphan
AOP Orphan
Slide 12: AOP Orphan
AOP Orphan 1. Calculated based on EURUSD exchange rate of 1.2858, being the average exchange rate for the financial year ending 31 December 2012 2. Unaudited
Slide 13: Why This Transaction Is Attractive For Elan
Why This Transaction Is Attractive For Elan • Fully integrated high growth orphan pharmaceuticals business • Strong regional and commercial platform in high growth markets • Multiple late stage orphan disease opportunities • Infrastructure lite (~145 FTE) • Targeted regional platform with diversifie
Slide 14: Newbridge
Newbridge
Slide 15: Elan / Newbridge Pharmaceuticals
Elan / Newbridge Pharmaceuticals • INVESTMENT: $40 million • RETURN: 48.3% of specialty therapeutics company in Middle East, Africa and Caspian Region (AfMET) • Venture backed specialty therapeutics company specializing in in-licensing, acquiring, registering and commercializing approved pharmaceuti
Slide 16: Emerging Market Opportunity
Emerging Market Opportunity • AOP – Central & Eastern Europe • NewBridge – Middle East, North Africa & Turkey • Combined AOP & Newbridge markets growing exponentially when compared with developed markets * Business Monitor International; E&Y EM Assessment, World Bank data, and expert opinion from L.
Slide 17: Speranza Therapeutics
Speranza Therapeutics
Slide 18: ELND005: Speranza Therapeutics
ELND005: Speranza Therapeutics* • Private company exclusively focused on ELND005 development Objective to file in lead indication – Agitation/Aggression in AD, ~ 2015/2016 Demonstrate POC in BPD and Down Syndrome for additional life cycle management • Irish domiciled entity with all current and futu
Slide 19: Capital Structure
Capital Structure
Slide 20: Pro Forma Summary Capitalization and Maturity Profile
Summary Pro Forma Maturity Profile Summary Capitalization Table ($ MM) (2) Pro Forma 31-Mar-13 Refinancing, D5, Theravance & AOP Acquisitions (1) Senior Notes $800 MM Cash & Cash Equivalents as of Mar-13 $556 MM PF Adj. for Transactions $669 MM Pro Forma Summary Capitalization and Maturity Profile $
Slide 21: Elan Today
Elan Today
Slide 22: Elan plc Objectives
Elan plc Objectives Tysabri THRX AOP Newbridge ELND005- Speranza P&L (Growth) Option Value of Late Stage Pipeline Diversification: Science-Molecules; Therapeutic Areas; Geographies Optimize & Leverage Business and Financial Structure
Slide 23: Irish Takeover Rules
Irish Takeover Rules As required by the Irish Takeover Rules, the Directors of Elan accept responsibility for the information contained in this presentation. To the best of their knowledge and belief (having taken all reasonable care to ensure such is the case); the information contained in this pre